NCT00207116已完成1 期
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Prediction of response to Erbitux with non small cell lung cancer
研究概览
简要总结
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Measurable disease tumor available for biopsies
- •Life expectancy of at least 3 months
排除标准
- •Known or documented brain metastases prior to Cetuximab therapy
研究组 & 干预措施
A
Experimental
干预措施: Cetuximab (Drug)
结局指标
主要结局
Prediction of response to Erbitux with non small cell lung cancer
次要结局
- Radiographic Response
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal CancerMetastatic Colorectal CancerNCT00207155Eli Lilly and Company110
已完成
2 期
A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee PainOsteoarthritisNCT01619150C4Pain39
Unknown
4 期
Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic PainNeuralgiaPostherpetic NeuralgiaNCT01264237Analgesic Solutions120
已完成
2 期
Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)OsteoarthritisNCT00242489Organon and Co1,167
进行中（未招募）
不适用
Erbitux Monotherapie bei Patienten mit lokoregional nicht behandelbarem Hepatozellulären Karzinom - Cetuximab Monotherapie beim HCCadvanced hepatocellular carcinoma (hcc) not amandable to regional therapies or metastatic diseaseEUCTR2005-000040-85-DEMedical School Hannover32